Patients with transthyretin amyloid cardiomyopathy taking tafamidis have less worsening of cardiac function than those on placebo, post hoc analysis of randomized results suggests.
The SELECT trial catapulted GLP-1 RAs into the forefront of CVD prevention, but cardiologists are making their own decisions about whether and how they might integrate these agents into practice.
Transcatheter tricuspid repair reduced valve regurgitation and improved quality of life at 1 year even for the sickest patients, but mortality remained high, new analysis of TRILUMINATE trial shows.
A stethoscope that uses AI is more sensitive to detecting signs of valvular heart disease than a standard stethoscope is in the hands of a primary care physician, a new study shows.